BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27845339)

  • 1. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
    Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
    Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.
    Kaur S; Chakraborty S; Baine MJ; Mallya K; Smith LM; Sasson A; Brand R; Guha S; Jain M; Wittel U; Singh SK; Batra SK
    PLoS One; 2013; 8(2):e55171. PubMed ID: 23383312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
    Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
    Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
    Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
    Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas.
    Kaur S; Baine MJ; Guha S; Ochi N; Chakraborty S; Mallya K; Thomas C; Crook J; Wallace MB; Woodward TA; Jain M; Singh S; Sasson AR; Skinner V; Raimondo M; Batra SK
    Pancreas; 2013 Apr; 42(3):494-501. PubMed ID: 23146921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
    Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
    J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas.
    Wang Y; Gao J; Li Z; Jin Z; Gong Y; Man X
    Int J Cancer; 2007 Dec; 121(12):2716-22. PubMed ID: 17708554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
    Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer.
    Liu D; Chang CH; Gold DV; Goldenberg DM
    Oncotarget; 2015 Feb; 6(6):4274-85. PubMed ID: 25595893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness.
    Ganguly K; Krishn SR; Rachagani S; Jahan R; Shah A; Nallasamy P; Rauth S; Atri P; Cox JL; Pothuraju R; Smith LM; Ayala S; Evans C; Ponnusamy MP; Kumar S; Kaur S; Batra SK
    Cancer Res; 2021 Jan; 81(1):91-102. PubMed ID: 33127746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.
    Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T
    Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.